When are the key readouts for the HDV program expected?

  • Morgan Stanley said three key studies are progressing as planned: Phase III ECLIPSE-1 is expected to report data in the fourth quarter of 2026, followed by Phase III ECLIPSE-2 and Phase IIb ECLIPSE-3, which are expected to report data in the first quarter of 2027. ECLIPSE-1 compares combination therapy with delayed treatment; ECLIPSE-2 is for patients who respond inadequately to existing drugs; and ECLIPSE-3 is a head-to-head comparison with an existing drug.
  • The company’s confidence in the combination therapy is based on Phase II SOLSTICE: after 48 weeks of treatment, 38% of patients achieved the composite endpoint of virologic response and ALT normalization, and 66% achieved a virologic response. ECLIPSE-3 is designed to demonstrate superiority, with the aim of securing favorable pricing and reimbursement terms in regions where the existing drug is approved.

What has VIR-5500’s progress changed?

  • The prostate-specific membrane antigen-targeting T-cell engager VIR-5500 met the proof-of-concept criteria set by its partner Astellas, which were not publicly disclosed; Morgan Stanley said this supports its advancement to late-stage development. Earlier studies showed a PSA50 response rate of 82%, a PSA90 response rate of 53%, and an objective response rate of 45% in patients with metastatic castration-resistant prostate cancer.
  • The company plans to initiate a Phase III program in 2027, evaluating patients in earlier and later lines of treatment; the later-line indication has received FDA Fast Track designation. This marks progress into the pivotal-trial stage, while clinical outcomes remain central to converting the pipeline into commercial value.

Is all pipeline progress still on the original timeline?

  • No. The company had originally planned to update data for the HER2-targeting T-cell engager VIR-5818 in the second half of 2026; it no longer expects to report data this year, and the timing is uncertain. The company is adjusting the monotherapy study in response to FDA feedback and adding a more homogeneous supplemental cohort to optimize the dose and dosing regimen; this reduces near-term pipeline data catalysts.

What assumptions underpin the cash runway and price target?

  • At the end of the third quarter of 2026, Vir held 901.3 million in cash and cash equivalents and also expected to receive 135 million in Gilead collaboration payments in the near term. The company expects these funds to support operations through the second half of 2028, providing a financial cushion for the clinical programs described above.
  • Morgan Stanley maintained its Overweight rating and a US$25 price target; the report listed a closing price of US$11.77 on 4 November 2026. Its valuation uses a 10% discount rate and a 1% terminal growth rate. The base case assumes combined risk-adjusted peak sales of about 1.5 billion for VIR-5500 and the HDV program in 2034; if all pipeline programs fail, the report’s bear case suggests the share price could fall below cash value per share.

Related topics